Skip to main content
ImageneBio, Inc. logo

ImageneBio, Inc. — Investor Relations & Filings

Ticker · IMA ISIN · US45175G1085 US Manufacturing
Open in API
Filings indexed 286 across all filing types
Latest filing 2026-05-07 Capital/Financing Update
Country US United States of America
Listing US IMA

About ImageneBio, Inc.

https://inmagenebio.com/

ImageneBio, Inc. is a clinical-stage biotechnology company that develops therapeutics for patients with immunological, autoimmune, and inflammatory diseases. The company's lead candidate is IMG-007, a next-generation investigational anti-OX40 monoclonal antibody. IMG-007 is designed with an extended half-life to target and inhibit OX40 receptor signaling without depleting T cells, aiming to provide a potential best-in-class treatment with enhanced efficacy, safety, and patient convenience.

Recent filings

Filing Released Lang Actions
424B3 - ImageneBio, Inc. (0001835579) (Filer)
Capital/Financing Update Classification · 90% confidence The document is a prospectus supplement filed pursuant to Rule 424(b)(3) relating to the proposed offer and resale of 2,508,337 shares of common stock under a registration statement. This is clearly part of a financing activity (capital raising) rather than an earnings report, management disclosure, or a regulatory certification. It is not a full financial report but a fundraising prospectus. Thus it falls under Capital/Financing Update (CAP).
2026-05-07 English
ARS - ImageneBio, Inc. (0001835579) (Filer)
Annual Report
2026-04-30 English
424B3 - ImageneBio, Inc. (0001835579) (Filer)
Capital/Financing Update Classification · 100% confidence The document is a Form 8-K Current Report filed by ImageneBio, Inc. It details the entry into a material definitive agreement, specifically a Securities Purchase Agreement for a private placement of pre-funded warrants and common stock. The filing includes descriptions of the transaction terms, registration rights, and related agreements. It is not a full financial report, earnings release, or management discussion, but rather a regulatory announcement of a capital raising event. The document is substantive and not merely a brief announcement or certification. Therefore, it fits the category of Capital/Financing Update filings, which cover company fundraising and financing activities.
2026-04-13 English
8-K - ImageneBio, Inc. (0001835579) (Filer)
Capital/Financing Update Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a Current Report used to announce major events that shareholders should know about. The content describes the entry into a material definitive agreement related to a Securities Purchase Agreement for a private placement financing, including details about pre-funded warrants and registration rights. It also includes information about unregistered sales of equity securities. There are no financial statements or comprehensive financial data presented, nor is this an earnings release or annual/interim report. The document is primarily an announcement of a capital raising transaction and related agreements. Therefore, it fits best under the category of Capital/Financing Update (CAP). The document length is over 10,000 characters and contains substantive details about the financing transaction, not just a brief announcement or reference to a report, so it is not an RPA or RNS. Hence, the classification is CAP with high confidence.
2026-04-13 English
4 - ImageneBio, Inc. (0001835579) (Issuer)
Director's Dealing
2026-03-18 English
8-K - ImageneBio, Inc. (0001835579) (Filer)
Board/Management Information Classification · 100% confidence The document is a Form 8-K filed with the SEC, dated March 12, 2026, reporting a change in senior management: the departure of Erin Butler as Principal Accounting Officer and the appointment of Bob Lally to that position. The content focuses exclusively on management changes without financial data or other report types. This matches the definition of Board/Management Information (MANG). The document length is 4662 characters, which is sufficient to contain substantive information about the management change. Therefore, the correct classification is MANG with high confidence.
2026-03-17 English

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.